Key result
Statin therapy can rarely cause statin-induced necrotizing autoimmune myopathy, a severe condition marked by muscle weakness and persistently elevated creatine kinase levels after discontinuation.
Case Report
This case report highlights the rare but severe complication of statin-induced necrotizing autoimmune myopathy, which requires recognition as it persists even after statin discontinuation.
Clinicians should consider this entity in refractory post-statin myopathy; case reports extend awareness but leave incidence and management open.
In the landscape of contemporary medicine, statins stand out as a cornerstone in the prevention and management of atherosclerotic cardiovascular diseases. By inhibiting the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase enzyme, statins effectively lower cholesterol levels, thus mitigating the risk of heart attacks and strokes.1 Despite their widespread adoption and generally well-tolerated nature, the clinical panorama of statin therapy is occasionally marred by side effects, including muscle-related adverse events. These range from relatively common and benign myalgias to the rare and severe statin-induced necrotizing autoimmune myopathy (SINAM), a condition marked by muscle weakness and profoundly elevated levels of creatine kinase (CK) that persist even after the discontinuation of the offending statin2 (Table 1).
No takes yet. Share an insight, caveat, or question.
Teichner et al. (2024) conducted a case report in Statin-induced necrotizing autoimmune myopathy (SINAM). Statins was evaluated. Statin therapy can rarely cause statin-induced necrotizing autoimmune myopathy, a severe condition marked by muscle weakness and persistently elevated creatine kinase levels after discontinuation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: